CHAPLE
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease) (NCT04209634) | Regeneron Pharmaceuticals | 2020-01-27 |
Track CHAPLE automatically
Every clearance here is in the API, with alerts when new ones post.